{"id":798551,"date":"2025-01-07T09:31:02","date_gmt":"2025-01-07T14:31:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-shareholders-meeting-results-2\/"},"modified":"2025-01-07T09:31:02","modified_gmt":"2025-01-07T14:31:02","slug":"clearmind-medicine-announces-shareholders-meeting-results-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-shareholders-meeting-results-2\/","title":{"rendered":"Clearmind Medicine Announces Shareholders Meeting Results"},"content":{"rendered":"<div class=\"mw_release\">\n<p>Vancouver, Canada, Jan.  07, 2025  (GLOBE NEWSWIRE) &#8212;  Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (\u201cClearmind\u201d or the \u201cCompany\u201d), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce that all of the matters put forward before shareholders for consideration and approval at its meeting held on January 6, 2025 (the \u201cMeeting\u201d), as set out in the Company\u2019s Management Information Circular dated December 1, 2024, were approved by the requisite majority of votes cast at the Meeting, including a resolution fixing the board of directors at five members, the election of directors of the Company for the ensuing year, to appoint Brightman Almagor Zohar &amp; Co., a firm in the Deloitte Global Network, as auditor of the Company, a resolution to establish and approve an omnibus equity incentive plan and a resolution allowing the directors, if they deem such an action to be in the best interest of shareholders, effect a consolidation (the \u201cConsolidation\u201d) of the common shares in the capital of the Company (the \u201cShares\u201d) on the basis of fifty (50) pre-Consolidation Shares for one (1) post-Consolidation Share, or such other lesser consolidation ratio as determined by the Company\u2019s board of directors.<\/p>\n<p>\n        <strong>About\u00a0Clearmind\u00a0Medicine Inc.<\/strong>\n      <\/p>\n<p>Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.<\/p>\n<p>The Company\u2019s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.<\/p>\n<p>Shares of Clearmind are listed for trading on Nasdaq under the symbol \u201cCMND\u201d and the Frankfurt Stock Exchange under the symbol \u201cCWY0.\u201d<\/p>\n<p>For further information visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_VNMwFY2QznTEktXREcw7DRpqcvtQp9KoY6hUmZ004wYUl_XnSlyKk2nE2lHWh0nk-lUpMFhu63QcIPgpEbBXK5dhnnRdZ_7dAzYZ4325RvvcMbbIpTyiFKeqU-Z0R_C\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/www.clearmindmedicine.com<\/u><\/a>\u00a0or contact:<\/p>\n<p>Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lIhQmMFkkNrihq8LIdFMb9I1f7bD2lhSY2542Ex98_GUAqkG4hMRXV_vtlf-ccQpxlwbKeGgMQfygdq68JLZ1XfXRMqfNghWL4HPm86ogZglINIvcmgpDztdhOT-mr4R\" rel=\"nofollow\" target=\"_blank\"><u>invest@clearmindmedicine.com<\/u><\/a><\/p>\n<p>Telephone: (604) 260-1566<br \/>US:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aRV_toEOrmSfaJlcI7LbYvTbDvy7SuOp-BHmC6wr1S9r_PBJhBQLAT0_PbcOOUgxw3KX5-ChcE-Ls7HrbI82Rd3ZtLux6_rOgrCeJWhWCwA=\" rel=\"nofollow\" target=\"_blank\"><u>CMND@crescendo-ir.com<\/u><\/a><\/p>\n<p>General Inquiries<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UKSkNESy160C11MXHgoXOacXQbwZMN9gYloLNzKQUK_RH6x76TTZiJPtLE5ol8oE3D9nS4Z4BV9eC5MlrvyiC7SrP500jp6M_HSfxFaj2R7H6ah-ktimqElXu-xUPfPn\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <u>Info@Clearmindmedicine.com<\/u><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MaV91OaRA8pj59MwHKMl5sM7RhNjXz1PPp3Tq5jmxsan-ogJ7j33E6MuDf2Ec24pOxjQj8HPF4P1LAiud9DtqRObnlxaMkl8ccU5B1mWGZnZxdh9CmRqiVCzRPhq8la2\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <u>www.Clearmindmedicine.com<\/u><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <strong>Forward-Looking Statements:<\/strong>\n      <\/p>\n<p>\n        <em>This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cbelieves,\u201d \u201cseeks,\u201d \u201cestimates\u201d and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management\u2019s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management\u2019s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company\u2019s reports filed from time to time with the Securities and Exchange Commission (\u201cSEC\u201d), including, but not limited to, the risks detailed in the Company\u2019s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.<\/em>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzg5NCM2NjgyNTc4IzUwMDA4NjkzNA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YWM1M2I0MGEtODY4NS00NzQ3LTkzOWQtN2M3YjIzZTc4YmM0LTUwMDA4NjkzNA==\/tiny\/Clearmind-Medicine-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Vancouver, Canada, Jan. 07, 2025 (GLOBE NEWSWIRE) &#8212; Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (\u201cClearmind\u201d or the \u201cCompany\u201d), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce that all of the matters put forward before shareholders for consideration and approval at its meeting held on January 6, 2025 (the \u201cMeeting\u201d), as set out in the Company\u2019s Management Information Circular dated December 1, 2024, were approved by the requisite majority of votes cast at the Meeting, including a resolution fixing the board of directors at five members, the election of directors of the Company for the ensuing year, to appoint Brightman Almagor Zohar &amp; Co., a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-shareholders-meeting-results-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Clearmind Medicine Announces Shareholders Meeting Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-798551","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Clearmind Medicine Announces Shareholders Meeting Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-shareholders-meeting-results-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clearmind Medicine Announces Shareholders Meeting Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Vancouver, Canada, Jan. 07, 2025 (GLOBE NEWSWIRE) &#8212; Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (\u201cClearmind\u201d or the \u201cCompany\u201d), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce that all of the matters put forward before shareholders for consideration and approval at its meeting held on January 6, 2025 (the \u201cMeeting\u201d), as set out in the Company\u2019s Management Information Circular dated December 1, 2024, were approved by the requisite majority of votes cast at the Meeting, including a resolution fixing the board of directors at five members, the election of directors of the Company for the ensuing year, to appoint Brightman Almagor Zohar &amp; Co., a &hellip; Continue reading &quot;Clearmind Medicine Announces Shareholders Meeting Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-shareholders-meeting-results-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-07T14:31:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzg5NCM2NjgyNTc4IzUwMDA4NjkzNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-shareholders-meeting-results-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-shareholders-meeting-results-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Clearmind Medicine Announces Shareholders Meeting Results\",\"datePublished\":\"2025-01-07T14:31:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-shareholders-meeting-results-2\\\/\"},\"wordCount\":670,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-shareholders-meeting-results-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzg5NCM2NjgyNTc4IzUwMDA4NjkzNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-shareholders-meeting-results-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-shareholders-meeting-results-2\\\/\",\"name\":\"Clearmind Medicine Announces Shareholders Meeting Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-shareholders-meeting-results-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-shareholders-meeting-results-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzg5NCM2NjgyNTc4IzUwMDA4NjkzNA==\",\"datePublished\":\"2025-01-07T14:31:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-shareholders-meeting-results-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-shareholders-meeting-results-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-shareholders-meeting-results-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzg5NCM2NjgyNTc4IzUwMDA4NjkzNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzg5NCM2NjgyNTc4IzUwMDA4NjkzNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-announces-shareholders-meeting-results-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clearmind Medicine Announces Shareholders Meeting Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clearmind Medicine Announces Shareholders Meeting Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-shareholders-meeting-results-2\/","og_locale":"en_US","og_type":"article","og_title":"Clearmind Medicine Announces Shareholders Meeting Results - Market Newsdesk","og_description":"Vancouver, Canada, Jan. 07, 2025 (GLOBE NEWSWIRE) &#8212; Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (\u201cClearmind\u201d or the \u201cCompany\u201d), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce that all of the matters put forward before shareholders for consideration and approval at its meeting held on January 6, 2025 (the \u201cMeeting\u201d), as set out in the Company\u2019s Management Information Circular dated December 1, 2024, were approved by the requisite majority of votes cast at the Meeting, including a resolution fixing the board of directors at five members, the election of directors of the Company for the ensuing year, to appoint Brightman Almagor Zohar &amp; Co., a &hellip; Continue reading \"Clearmind Medicine Announces Shareholders Meeting Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-shareholders-meeting-results-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-07T14:31:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzg5NCM2NjgyNTc4IzUwMDA4NjkzNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-shareholders-meeting-results-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-shareholders-meeting-results-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Clearmind Medicine Announces Shareholders Meeting Results","datePublished":"2025-01-07T14:31:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-shareholders-meeting-results-2\/"},"wordCount":670,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-shareholders-meeting-results-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzg5NCM2NjgyNTc4IzUwMDA4NjkzNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-shareholders-meeting-results-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-shareholders-meeting-results-2\/","name":"Clearmind Medicine Announces Shareholders Meeting Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-shareholders-meeting-results-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-shareholders-meeting-results-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzg5NCM2NjgyNTc4IzUwMDA4NjkzNA==","datePublished":"2025-01-07T14:31:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-shareholders-meeting-results-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-shareholders-meeting-results-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-shareholders-meeting-results-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzg5NCM2NjgyNTc4IzUwMDA4NjkzNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzg5NCM2NjgyNTc4IzUwMDA4NjkzNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-announces-shareholders-meeting-results-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Clearmind Medicine Announces Shareholders Meeting Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=798551"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798551\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=798551"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=798551"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=798551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}